APGE - NASDAQ

Apogee Therapeutics, Inc.

APGE·NASDAQ

$84.19

+3.0%

HealthcareBiotechnology

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$5.21B

EPS-4.2200

P/E Ratio-19.95

Earnings Date08/10/2026

937.13M

Assets

24%

3Y+516.0%

5Y+516.0%

10Y+516.0%

33.25M

Total Liabilities

-11%

3Y+233.0%

5Y+233.0%

10Y+233.0%

903.88M

Total Equity

26%

3Y+536.0%

5Y+536.0%

10Y+536.0%

Apogee Therapeutics, Inc. Funding & Solvency Profile

APGE · NASDAQ

Current Assets

Cash & Cash Equivalents131.55M

Net Receivables0.00

Inventory0.00

Other Current Assets11.17M

Total Current Assets741 M

Non-Current Assets

Property, Plant & Equipment14.38M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets181.40M

Total Non-Current Assets196 M

Total Assets

937.13M

Financial Health Analysis

Current Ratio

26.57x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.04x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

713 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

79% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Apogee Therapeutics, Inc. Balance Sheet

APGE • NASDAQ

Apogee Therapeutics, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	131.5M	141.8M	118.3M	151.9M
Short-Term Investments	598.6M	378.9M	277.1M	0.0
Cash & Short-Term Investments	730.2M	520.7M	395.5M	151.9M
Net Receivables	0.0	4.7M	1.2M	0.0
Accounts Receivables	0.0	4.7M	1.2M	0.0
Prepaids	0.0	2.6M	1.7M	108K
Other Current Assets	11.2M	1.7M	0.0	57K
Total Current Assets	741.4M	529.7M	398.4M	152.1M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	14.4M	13.3M	2.6M	0.0
Long-Term Investments	0.0	210.4M	0.0	0.0
Other Non-Current Assets	181.4M	498K	401K	0.0
Total Non-Current Assets	195.8M	224.2M	3M	0.0
Total Assets	937.1M	754M	401.4M	152.1M
LIABILITIES
CURRENT LIABILITIES
Total Payables	1.2M	1.1M	2.1M	418K
Accounts Payable	1.2M	1.1M	2.1M	418K
Accrued Expenses	0.0	1.9M	167K	9M
Short Term Debt	3.5M	3.2M	1.1M	0.0
Other Current Liabilities	23.2M	22.4M	17.1M	515K
Total Current Liabilities	27.9M	28.6M	20.6M	10M
NON-CURRENT LIABILITIES
Long Term Debt	5.3M	0.0	0.0	0.0
Total Non-Current Liabilities	5.3M	8.6M	933K	0.0
Capital Lease Obligations	0.0	8.6M	933K	0.0
Total Liabilities	33.3M	37.2M	21.5M	10M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	177.5M
Common Stock	1K	1K	0.0	2.3M
Additional Paid-In Capital	0.0	1B	503.4M	0.0
Retained Earnings	-561.8M	-305.9M	-123.8M	-39.8M
Accumulated Other Comprehensive Income/Loss	1.1M	915K	329K	2.1M
Other Total Stockholders' Equity	1.5B	0.0	0.0	0.0
Total Stockholders' Equity	903.9M	716.8M	379.9M	142.1M
Total Equity	903.9M	716.8M	379.9M	142.1M
SUMMARY
Total Liabilities & Equity	937.1M	754M	401.4M	152.1M
Total Investments	598.6M	589.3M	277.1M	0.0
Total Debt	8.8M	11.8M	2M	0.0
Net Debt	-122.7M	-130M	-116.3M	-151.9M
Shares Outstanding	54,833,587	54,833,587	54,833,587	54,833,587

SEC Filings

APGE - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 27, 2026	May 26, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 27, 2026	May 27, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 11, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 11, 2026	May 11, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 24, 2026	April 21, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 24, 2026	June 09, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 25, 2026	March 24, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 23, 2026	March 23, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 02, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 02, 2026	March 02, 2026	2026	View Filing

Showing 1 to 10 of 53 filings

Related Guides

Blog Categories

Continue your APGE research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.